Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
- Sponsor
- National University Hospital, Singapore
- Study ID
- NCT03813394
- Phase
- PHASE1/PHASE2
- Status
- Active Not Recruiting
Conditions
- Locally Recurrent Cancer
- Metastatic Nasopharyngeal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- pembrolizumab — DRUG-Pembrolizumab in Solution for Injection
- bevacizumab — DRUG* Bevacizumab in Concentrate for Solution * Bevacizumab in Concentrate for Solution
Study Details
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
Key Dates
- First listed
- Jan 23, 2019
- Start date
- May 1, 2019
- Status verified
- Nov 2024
- Primary completion
- Jul 31, 2024
- Completion
- Jun 1, 2025
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Arm AIntravenous pembrolizumab alone,D8 of 21-day cycle.
- Experimental: Treatment Arm BIntravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
Primary Outcome Measure
Primary endpoint of ORR [ Time Frame: 2 years ]